At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
REGENECYTE +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
In Brief
A Phase 2 clinical trial evaluating REGENECYTE and Placebo for Long COVID and 2 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLong COVID, Post-COVID Syndrome, Post COVID-19 Condition
CountriesUnited States
CollaboratorsStemCyte Taiwan Co., Ltd.
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedJan 2023
Enrollment StartMay 2023
Primary CompletionJul 2024
Study CompletionFeb 2025
TodayJul 2026
First PostedJan 12, 2023
Enrollment StartMay 4, 2023
Primary CompletionJul 26, 2024
Study CompletionFeb 27, 2025
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.5 years ago
Interventions
REGENECYTEbiological
HPC, Cord Blood
Placebobiological
Normal Saline